[
  {
    "claim": "The Facebook Reel is from David A. Sinclair and promotes Lifespan Magazine / Lifespan.com.",
    "label": "Confirmed by public metadata",
    "finding": "Facebook OpenGraph and yt-dlp metadata identify the source as David A. Sinclair and describe a Lifespan Magazine promotion."
  },
  {
    "claim": "Lifespan says the magazine is written by scientists and covers longevity science.",
    "label": "Supported as publisher claim",
    "finding": "Lifespan.com states the magazine has in-depth features about longevity science written by scientists advancing the field. This is a publication-positioning claim, not a clinical recommendation."
  },
  {
    "claim": "The “information theory of aging” is a real scientific framework associated with Sinclair’s work.",
    "label": "Real research program; debated interpretation",
    "finding": "Sinclair’s site points to Nature 2020 vision-restoration work and Cell 2023 epigenetic-information work. These are serious preclinical/biological studies, but they do not prove routine human age reversal."
  },
  {
    "claim": "Partial reprogramming / age-reversal ideas are entering human trials.",
    "label": "Narrowly supported, needs caution",
    "finding": "Search and source trail point to small disease-targeted eye/optic-nerve trial reporting, not a proven whole-body rejuvenation treatment. A trial starting is not the same as efficacy or safety being established."
  },
  {
    "claim": "A multivitamin-mineral supplement may slow aging.",
    "label": "Interesting trial signal, not universal advice",
    "finding": "COSMOS-related PubMed records include cognition and epigenetic-aging findings. NIH-style supplement guidance still cautions that supplements are not substitutes for diet/medical care and can have risks/interactions."
  },
  {
    "claim": "Readers can use the Reel as direct personal health advice.",
    "label": "Not supported",
    "finding": "The Reel is a magazine promotion. Managing Expectations treats it as a source lead; individual supplements, reprogramming therapies and longevity protocols require clinician/pharmacist review."
  }
]